| Summary of Finite-Lived Intangible Assets |
The following table summarizes our Intangible assets, net: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | June 30, 2024 | | December 31, 2023 | | (in millions) | | Gross
Carrying
Amount | | Accumulated
Amortization | | Foreign Currency Translation Adjustment | | Net
Carrying Amount | | Gross
Carrying
Amount | | Accumulated
Amortization | | Foreign Currency Translation Adjustment | | Net
Carrying Amount | | Finite-lived assets: | | | | | | | | | | | | | | | | | | Intangible asset – sofosbuvir | | $ | 10,720 | | | $ | (7,399) | | | $ | — | | | $ | 3,321 | | | $ | 10,720 | | | $ | (7,050) | | | $ | — | | | $ | 3,670 | | Intangible asset – axicabtagene ciloleucel | | 7,110 | | | (2,517) | | | — | | | 4,593 | | | 7,110 | | | (2,314) | | | — | | | 4,796 | | Intangible asset – Trodelvy | | 11,730 | | | (2,543) | | | — | | | 9,187 | | | 11,730 | | | (2,002) | | | — | | | 9,728 | | Intangible asset – Hepcludex | | 845 | | | (286) | | | — | | | 559 | | | 845 | | | (243) | | | — | | | 602 | | | Other | | 1,414 | | | (883) | | | 1 | | | 533 | | | 1,414 | | | (827) | | | 1 | | | 588 | | | Total finite-lived assets | | 31,819 | | | (13,628) | | | 1 | | | 18,192 | | | 31,819 | | | (12,436) | | | 1 | | | 19,384 | | Indefinite-lived assets – IPR&D(1) | | 4,640 | | | — | | | — | | | 4,640 | | | 7,070 | | | — | | | — | | | 7,070 | | | Total intangible assets | | $ | 36,459 | | | $ | (13,628) | | | $ | 1 | | | $ | 22,832 | | | $ | 38,889 | | | $ | (12,436) | | | $ | 1 | | | $ | 26,454 | |
_______________________________ (1) The Indefinite-lived assets – IPR&D balance as of December 31, 2023 was comprised of $5.9 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. See “2024 IPR&D Impairment” below for 2024 activity.
|
| Summary of Indefinite-Lived Intangible Assets |
The following table summarizes our Intangible assets, net: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | June 30, 2024 | | December 31, 2023 | | (in millions) | | Gross
Carrying
Amount | | Accumulated
Amortization | | Foreign Currency Translation Adjustment | | Net
Carrying Amount | | Gross
Carrying
Amount | | Accumulated
Amortization | | Foreign Currency Translation Adjustment | | Net
Carrying Amount | | Finite-lived assets: | | | | | | | | | | | | | | | | | | Intangible asset – sofosbuvir | | $ | 10,720 | | | $ | (7,399) | | | $ | — | | | $ | 3,321 | | | $ | 10,720 | | | $ | (7,050) | | | $ | — | | | $ | 3,670 | | Intangible asset – axicabtagene ciloleucel | | 7,110 | | | (2,517) | | | — | | | 4,593 | | | 7,110 | | | (2,314) | | | — | | | 4,796 | | Intangible asset – Trodelvy | | 11,730 | | | (2,543) | | | — | | | 9,187 | | | 11,730 | | | (2,002) | | | — | | | 9,728 | | Intangible asset – Hepcludex | | 845 | | | (286) | | | — | | | 559 | | | 845 | | | (243) | | | — | | | 602 | | | Other | | 1,414 | | | (883) | | | 1 | | | 533 | | | 1,414 | | | (827) | | | 1 | | | 588 | | | Total finite-lived assets | | 31,819 | | | (13,628) | | | 1 | | | 18,192 | | | 31,819 | | | (12,436) | | | 1 | | | 19,384 | | Indefinite-lived assets – IPR&D(1) | | 4,640 | | | — | | | — | | | 4,640 | | | 7,070 | | | — | | | — | | | 7,070 | | | Total intangible assets | | $ | 36,459 | | | $ | (13,628) | | | $ | 1 | | | $ | 22,832 | | | $ | 38,889 | | | $ | (12,436) | | | $ | 1 | | | $ | 26,454 | |
_______________________________ (1) The Indefinite-lived assets – IPR&D balance as of December 31, 2023 was comprised of $5.9 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. See “2024 IPR&D Impairment” below for 2024 activity.
|